Wire flash
FinanceNovo Nordisk sues Eli Lilly over false weight loss drug advertising
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Novo Nordisk filed a lawsuit against rival Eli Lilly on Tuesday in federal district court in New Jersey, accusing the company of false advertising regarding the performance of its weight loss drugs. The lawsuit alleges that Lilly intentionally selected outdated studies to claim that its drugs Mounjaro and Zepbound lead to significantly more weight loss than Novo Nordisk’s Ozempic and other treatments. This legal action highlights the intense competition in the rapidly growing weight loss drug market, where both companies are major players. The case centers on the accuracy of comparative advertising claims, with Novo Nordisk seeking to challenge what it views as misleading marketing tactics by Lilly.
Source report
Drugmaker Novo Nordisk filed a lawsuit against rival Eli Lilly on Tuesday, accusing the company of false advertising regarding the performance of its weight loss medications.
The lawsuit, filed in federal district court in New Jersey, alleges that Lilly intentionally selected outdated studies to claim that its drugs Mounjaro and Zepbound lead to significantly more weight loss than Novo Nordisk’s Ozempic and [additional drug name not provided in original text].
Source
Just In NewsWestern
Part of this Story
Novo Nordisk sues Eli Lilly over weight loss drug advertising